Any current/future new fundraising through debt or equity?

There is no explicit mention of any new fundraising through debt or equity in the transcript. The company expects to manage its net debt level below Rs. 550 crore throughout the year, despite ongoing capex to restore the Vashivali facility. Capex related to recovery of the Vashivali factory will be partially reimbursed by insurance, though some cash flow impact is anticipated. Discussions around capex mainly focus on facility restoration and expansion (Indonesia, Europe) rather than raising new external funds. The company expects improved free cash flow from normalized inventory and operations

Any current/future capex/capital investment/strategic investment?

Capital investment of $4-5 million was made in the Indonesia facility, expected to start full production from June, servicing $10-12 million revenue initially. Evaluation of a €3-4 million capex plan for expanding European fragrance capacity, aiming to support growth in Europe, Middle East, North Africa, and West Africa. Capex decisions for European subsidiary are under evaluation, with plans dependent on demand and strategic considerations. Ongoing investments in R&D across Italy (Europe), India, and Indonesia to support product development, sales, and local manufacturing. Restoration capex p

Future growth expectations in sales/revenue/volumes?

The company expects a continued 12% CAGR growth over the next few years across global business, including domestic, Southeast Asia, and European segments. Southeast Asia growth is expected to accelerate post-commissioning of the new Indonesia facility, improving speed to market and customer confidence. European operations are expanding, targeting new geographies like Germany, East Europe, and adjacent countries. The recent large MNC account provides a significant boost, with $10 million+ sales projected for FY25 and further growth potential. The company aims to increase growth beyond s

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a sustained revenue growth rate of around 12% CAGR for FY25 and the midterm, driven by product development, R&D, and geographic expansion (India, Southeast Asia, Europe, US). Southeast Asia operations, particularly the new Indonesian facility, are expected to accelerate growth and improve customer confidence due to local delivery advantages. EBITDA margins are expected to improve as operating leverage benefits from restored Vashivali factory and ramp-up of alternate sites take effect. Gross margins at current levels (~44%-45%) are sustainable with no significant expec

Current/ Expected Orderbook/ Pending Orders?

Current order book: USD 10 million on an annual basis (Kedar Vaze, Page 16). This USD 10 million is part of a larger potential order book valued at USD 100 million; USD 10 million has already been secured (Page 16). The USD 10 million order book is expected to be executed over the coming year (Page 16). Growth expectations for the order book involve continuing engagement with clients to secure additional business beyond the already bagged USD 10 million (Page 16). The company expects to build on this order book progressively, working on multi-year contracts with clients (Page 16). Southeast As

IN US

Sale is live|00:00:00left today

S H Kelkar & Company LtdQ1 FY24Chemicals & Petrochemicals

S H Kelkar & Company Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹135P/E: 38.1Market Cap: ₹1.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company expects a continued 12% CAGR growth over the next few years across global business, including domestic, Southeast Asia, and European segments.
→Southeast Asia growth is expected to accelerate post-commissioning of the new Indonesia facility, improving speed to market and customer confidence.
→European operations are expanding, targeting new geographies like Germany, East Europe, and adjacent countries.
→The recent large MNC account provides a significant boost, with $10 million+ sales projected for FY25 and further growth potential.
→The company aims to increase growth beyond saturated markets (8%-10%) by tapping new geographies and customers to achieve mid-teen growth rate.
→Industry trends remain positive with growing rural FMCG demand and international business expansion.
→Short-term sales growth may be impacted by the Vashivali factory fire incident but expected to recover in subsequent quarters.

Margin guidance

Category 3

→The company targets a sustained revenue growth rate of around 12% CAGR for FY25 and the midterm, driven by product development, R&D, and geographic expansion (India, Southeast Asia, Europe, US).
→Southeast Asia operations, particularly the new Indonesian facility, are expected to accelerate growth and improve customer confidence due to local delivery advantages.
→EBITDA margins are expected to improve as operating leverage benefits from restored Vashivali factory and ramp-up of alternate sites take effect.
→Gross margins at current levels (~44%-45%) are sustainable with no significant expected improvement long-term.
→Operating profit margins (EBITDA) may see margin expansion medium to long term due to productivity and cost measures, despite short-term impacts from fire-related operational changes.
→EPS growth is expected to follow improved profitability and revenue growth, supported by deleveraging and better cash flows.
→The company is cautious on short-term growth spikes; it anticipates continuous incremental growth rather than sudden large jumps.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any new fundraising through debt or equity in the transcript.
→The company expects to manage its net debt level below Rs. 550 crore throughout the year, despite ongoing capex to restore the Vashivali facility.
→Capex related to recovery of the Vashivali factory will be partially reimbursed by insurance, though some cash flow impact is anticipated.
→Discussions around capex mainly focus on facility restoration and expansion (Indonesia, Europe) rather than raising new external funds.
→The company expects improved free cash flow from normalized inventory and operations, which should help reduce debt.
→No plans for equity fundraising were mentioned during the Q&A or management comments.

Order book

Yes

→Current order book: USD 10 million on an annual basis (Kedar Vaze, Page 16).
→This USD 10 million is part of a larger potential order book valued at USD 100 million; USD 10 million has already been secured (Page 16).
→The USD 10 million order book is expected to be executed over the coming year (Page 16).
→Growth expectations for the order book involve continuing engagement with clients to secure additional business beyond the already bagged USD 10 million (Page 16).
→The company expects to build on this order book progressively, working on multi-year contracts with clients (Page 16).
→Southeast Asia and Europe are key regions for growth, with expansions ongoing, which may contribute to growing order books (Pages 5, 15).

Capex plans

Yes

→Capital investment of $4-5 million was made in the Indonesia facility, expected to start full production from June, servicing $10-12 million revenue initially.
→Evaluation of a €3-4 million capex plan for expanding European fragrance capacity, aiming to support growth in Europe, Middle East, North Africa, and West Africa.
→Capex decisions for European subsidiary are under evaluation, with plans dependent on demand and strategic considerations.
→Ongoing investments in R&D across Italy (Europe), India, and Indonesia to support product development, sales, and local manufacturing.
→Restoration capex planned for the Vashivali fragrance factory following fire incident, with insurance coverage expected to reimburse a substantial portion; exact plans and timing are pending.
→Focus on backward integration and cost reduction projects ongoing in India to improve productivity and margins.

How does S H Kelkar & Company Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1S H Kelkar & Company Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like S H Kelkar & Company Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio